Vor Biopharma Inc. (VOR) stock
VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$19.42+0.10 (+0.52%)
Close on Nov 13, 2026Market cap $1.19BP/E –Yield –
Vor Biopharma total assets
Total assets on the balance sheet at the end of each period.
Vor Biopharma's total assets was $496.31M at Sep 30, 2026. For fiscal 2025 it was $464.13M, up 224.8% from the year before. The highest annual figure on record is $464.13M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $464.13M | +224.8% |
| FY2024 | Dec 31, 2024 | $142.89M | -27.9% |
| FY2023 | Dec 31, 2023 | $198.13M | -33.8% |
| FY2022 | Dec 31, 2022 | $299.37M | +23.4% |
| FY2021 | Dec 31, 2021 | $242.59M | +219.6% |
| FY2020 | Dec 31, 2020 | $75.91M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $496.31M | +181.6% |
| Q2 FY2026 | Jun 30, 2026 | $481.05M | +134.2% |
| Q1 FY2026 | Mar 31, 2026 | $506.75M | +363.6% |
| Q4 FY2025 | Dec 31, 2025 | $464.13M | +224.8% |
| Q3 FY2025 | Sep 30, 2025 | $176.24M | +51.9% |
| Q2 FY2025 | Jun 30, 2025 | $205.37M | +45.0% |
| Q1 FY2025 | Mar 31, 2025 | $109.31M | -34.6% |
| Q4 FY2024 | Dec 31, 2024 | $142.89M | -27.9% |
| Q3 FY2024 | Sep 30, 2024 | $115.99M | -48.0% |
| Q2 FY2024 | Jun 30, 2024 | $141.59M | -43.6% |
| Q1 FY2024 | Mar 31, 2024 | $167.03M | -39.8% |
| Q4 FY2023 | Dec 31, 2023 | $198.13M | -33.8% |
| Q3 FY2023 | Sep 30, 2023 | $223.02M | +8.1% |
| Q2 FY2023 | Jun 30, 2023 | $250.99M | +11.7% |
| Q1 FY2023 | Mar 31, 2023 | $277.53M | +18.5% |
| Q4 FY2022 | Dec 31, 2022 | $299.37M | +23.4% |
| Q3 FY2022 | Sep 30, 2022 | $206.37M | -20.2% |
| Q2 FY2022 | Jun 30, 2022 | $224.62M | -18.4% |
| Q1 FY2022 | Mar 31, 2022 | $234.27M | -20.0% |
| Q4 FY2021 | Dec 31, 2021 | $242.59M | +219.6% |
| Q3 FY2021 | Sep 30, 2021 | $258.63M | – |
| Q2 FY2021 | Jun 30, 2021 | $275.14M | – |
| Q1 FY2021 | Mar 31, 2021 | $292.94M | – |
| Q4 FY2020 | Dec 31, 2020 | $75.91M | – |
See a number that looks wrong?